New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
08:34 EDTABIOARCA Biopharma announces GENETIC-AF CTA accepted by Health Canada
ARCA biopharma announced that the company’s Clinical Trial Application for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in Q4. ARCA is evaluating Gencaro as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the U.S. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically targeted therapy for the prevention of atrial fibrillation.
News For ABIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
08:33 EDTABIOARCA Biopharma activates first Canadian genetic-AF clinical trial site
Subscribe for More Information
December 10, 2014
08:33 EDTABIOARCA Biopharma receives FDA orphan drug designation for rNaPc2
Subscribe for More Information
December 9, 2014
10:40 EDTABIOARCA Biopharma treatment of Ebola granted orphan designation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use